Investigation of the Growth Inhibitory Effect and Mechanism of Quercetin and Isorhamnetin in Prostate Cancer

• Main Authors: 林哲維 LIN, ZHE, WEI, 林哲維
• Other Authors: Huei-Ju Ting
• Format: Others
• Language: zh-TW
• Published: 2019
• Online Access: http://ndltd.ncl.edu.tw/handle/u2b2pq

碩士 === 國立臺南大學 === 生物科技學系碩士班 === 107 === Prostate cancer is a malignant tumor ranked within top ten cancer in male. Most prostate cancers grow at a slower rate, but some prostate cancers still grow relatively fast. Prostate cancer is treated with surgical castration, hormonal therapy, chemotherapy and radiation therapy. These therapy can reduce mortality rate of patient, but once cancer recurrent and metastasize to bones and lymph nodes, these treatments only can delay the patient's survival time and fail to achieve effective treatment. Currently, two types of treatments for recurrent prostate cancer, including gene targeting and natural products are under investigation. The purpose of this study is to identify natural products those are effective in inhibiting cancer growth. Among several flavonoids tested, quercetin and its methylated derivative, isorhamnetin, were effective in inhibiting prostate cancer cell survival. Further investigating the effect on cell cycle progression demonstrate that these two drugs both induced G2/M arrest . This effect, however, can only be observed in normal but not cancerous prostate cell. Next, the expression of multidrug resistant proteins, those are known to be important in cancer developing drug resistance, were measured in prostate cells . The result demonstrated that multidrug protein expression was correlated to drug sensitivity among three cell tested. However, the inhibitor of multidrug resistant proteins did not promote cytotoxicity of these two drugs. The mechanism via which isorhamnetin gains higher cytotoxicity than quercetin demands further study.